🚀 VC round data is live in beta, check it out!
Oruka Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oruka Therapeutics and similar public comparables like Sionna Therapeutics, Nanobiotix, Square Pharma, Agios Pharmaceuticals and more.
Oruka Therapeutics Overview
About Oruka Therapeutics
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Founded
2024
HQ
Employees
36
Website
Sectors
Financials (LTM)
EV
$1B
Oruka Therapeutics Financials
Oruka Therapeutics reported last 12-month revenue of — and negative EBITDA of ($130M).
In the same LTM period, Oruka Therapeutics generated — in gross profit, ($130M) in EBITDA losses, and had net loss of ($117M).
Revenue (LTM)
Oruka Therapeutics P&L
In the most recent fiscal year, Oruka Therapeutics reported revenue of — and net income of —.
Oruka Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($130M) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($117M) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Oruka Therapeutics Stock Performance
Oruka Therapeutics has current market cap of $2B, and enterprise value of $1B.
Market Cap Evolution
Oruka Therapeutics' stock price is $33.63.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $2B | 0.0% | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOruka Therapeutics Valuation Multiples
Oruka Therapeutics trades at (9.8x) EV/EBITDA.
Oruka Therapeutics Financial Valuation Multiples
As of March 7, 2026, Oruka Therapeutics has market cap of $2B and EV of $1B.
Equity research analysts estimate Oruka Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oruka Therapeutics has a P/E ratio of (13.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/EBITDA | (9.8x) | XXX | — | XXX | XXX | XXX |
| EV/EBIT | (9.9x) | XXX | — | XXX | XXX | XXX |
| P/E | (13.9x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oruka Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Oruka Therapeutics Margins & Growth Rates
Oruka Therapeutics' revenue in the last fiscal year grew by —.
Oruka Therapeutics' revenue per employee in the last FY averaged $0.0M.
Oruka Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 25% | XXX | — | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Oruka Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sionna Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanobiotix | XXX | XXX | XXX | XXX | XXX | XXX |
| Square Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Agios Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunocore Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oruka Therapeutics M&A Activity
Oruka Therapeutics acquired XXX companies to date.
Last acquisition by Oruka Therapeutics was on XXXXXXXX, XXXXX. Oruka Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Oruka Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOruka Therapeutics Investment Activity
Oruka Therapeutics invested in XXX companies to date.
Oruka Therapeutics made its latest investment on XXXXXXXX, XXXXX. Oruka Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Oruka Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oruka Therapeutics
| When was Oruka Therapeutics founded? | Oruka Therapeutics was founded in 2024. |
| Where is Oruka Therapeutics headquartered? | Oruka Therapeutics is headquartered in United States. |
| How many employees does Oruka Therapeutics have? | As of today, Oruka Therapeutics has over 36 employees. |
| Who is the CEO of Oruka Therapeutics? | Oruka Therapeutics' CEO is Lawrence Otto Klein. |
| Is Oruka Therapeutics publicly listed? | Yes, Oruka Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Oruka Therapeutics? | Oruka Therapeutics trades under ORKA ticker. |
| When did Oruka Therapeutics go public? | Oruka Therapeutics went public in 2024. |
| Who are competitors of Oruka Therapeutics? | Oruka Therapeutics main competitors are Sionna Therapeutics, Nanobiotix, Square Pharma, Agios Pharmaceuticals. |
| What is the current market cap of Oruka Therapeutics? | Oruka Therapeutics' current market cap is $2B. |
| Is Oruka Therapeutics profitable? | No, Oruka Therapeutics is not profitable. |
| What is the current EBITDA of Oruka Therapeutics? | Oruka Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Oruka Therapeutics? | Current EBITDA multiple of Oruka Therapeutics is (9.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.